



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/799,941	03/11/2004	Martha G. Welch	19240.477 US2	8041
56949 7590 07/21/2010 WilmerHale/Columbia University 399 PARK AVENUE NEW YORK, NY 10022				
EXAMINER				
KOSAR, ANDREW D				
ART UNIT		PAPER NUMBER		
1654				
NOTIFICATION DATE		DELIVERY MODE		
07/21/2010		ELECTRONIC		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

teresa.carvalho@wilmerhale.com  
whipusptopairs@wilmerhale.com

<b><i>Examiner-Initiated Interview Summary</i></b>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 2px;">Application No. 10/799,941</td> <td style="width: 50%; padding: 2px;">Applicant(s) WELCH ET AL.</td> </tr> <tr> <td style="padding: 2px;">Examiner ANDREW D. KOSAR</td> <td style="padding: 2px;">Art Unit 1654</td> </tr> </table>	Application No. 10/799,941	Applicant(s) WELCH ET AL.	Examiner ANDREW D. KOSAR	Art Unit 1654
Application No. 10/799,941	Applicant(s) WELCH ET AL.				
Examiner ANDREW D. KOSAR	Art Unit 1654				

**All Participants:**  
 (1) ANDREW D. KOSAR.  
 (2) Julia Grimes.

**Status of Application:** after response to interview  
 (3) \_\_\_\_\_.  
 (4) \_\_\_\_\_.

**Date of Interview:** 28 June 2010      **Time:** 11:00

**Type of Interview:**  
☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant    ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes    ☒ No  
 If Yes, provide a brief description: \_\_\_\_\_

**Part I.**

Rejection(s) discussed:  
*potential 103 and 112*

Claims discussed:  
*all, in general*

Prior art documents discussed:  
*Hollander*

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:  
*See Continuation Sheet*

**Part III.**

☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

/Andrew D Kosar/  
Primary Examiner, Art Unit 1654

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Discussed amendments to the claims which would place the application in condition for allowance. Claim 26, being amended to inflammatory bowel disease, and new claim 32, drawn to treating primary biliary cirrhosis, would be allowable, finding sufficient enablement in the specification as filed. All remaining claims would be cancelled and the restriction would be withdrawn only to the extent 26 and 'new' claim 32 would be rejoined. The examiner indicated that Hollander (attached) would have formed the basis of the obviousness rejection, similar to that which was previously set forth, however it was published 1/03. Applicant's representative requested time to consult with the client/foreign associate. In the interview of 7/17/10, the examiner indicated that dependent claims from 26 and 32 would be entered and that 'inflammatory' would replace 'irritable' in claim 26, as it is the exemplified embodiment of the specification and appeared to be a typographical error, as irritable bowel disease is not a 'real' condition, but rather inflammatory bowel disease or irritable bowel syndrome. To the examiner, it was clear from the specification examples that 'inflammatory' was the correct term. Agreement was reached on allowable subject matter in an interview of 7/17/10.